IL1B and COVID-19: While the mainstay of the treatment is glucocorticoids IL-1 antagonists are effective as both treatment of resistant disease and steroid-sparing agents.3,4 The effectiveness of anakinra on COVID-19 infection has been reported in a few studies.5–7 Canakinumab was investigated for myocarditis in COVID-19 patients in one study8 and canakinumab was associated with better outcomes in another.9 Herein we report on five cases of COVID-19 infection in patients with inflammatory disorders (3 FMF,1 AOSD,1 sJIA) who contracted the infection while being treated with canakinumab.